Experts Call for Lung-RADS Updates Amid Concern About Certain Incidental Findings

Why It Matters

Updating Lung‑RADS could improve early detection of non‑pulmonary cancers and reduce unnecessary follow‑ups, influencing care for millions of screened patients.

Key Takeaways

• 7% of scans showed cancerous incidental findings
• 3% diagnosed with extrapulmonary cancer within one year
• Urinary cancers highest risk among incidental findings
• Lung‑RADS S modifier lacks specificity for non‑pulmonary cancers
• 14 million Americans eligible for lung‑cancer screening

Pulse Analysis

The recent Brown University study shines a light on an often‑overlooked dimension of low‑dose CT lung screening: incidental findings that signal cancers outside the lungs. While prior work suggested one‑third of scans reveal some abnormality, this analysis quantifies the true clinical relevance, showing that 7% of examinations contain significant incidental findings that are malignant, and a subset—about 3%—progress to a confirmed extrapulmonary cancer within a year. By classifying these cancers using SEER organ‑system categories, the researchers identified urinary tract malignancies as the most common, with lymphoma and leukemia trailing. This granular risk profile provides physicians with data to differentiate between benign anomalies and those warranting prompt investigation.

The implications for Lung‑RADS, the reporting framework guiding radiologists, are profound. Currently, the S modifier flags any suspicious incidental finding without distinguishing its likelihood of representing a serious malignancy. Incorporating the new evidence could refine the modifier, enabling more precise recommendations for follow‑up imaging or specialist referral. Such a revision would help avoid the cascade of unnecessary procedures for low‑risk anomalies while ensuring high‑risk lesions receive timely attention, ultimately balancing patient safety with cost‑effectiveness.

From a health‑system perspective, even a modest increase in detection accuracy could affect millions. With approximately 14 million Americans meeting eligibility criteria for lung‑cancer screening, the aggregate number of potentially missed or over‑investigated incidental cancers is sizable. Policymakers, insurers, and clinical guideline committees must weigh the benefits of a more nuanced Lung‑RADS against the operational challenges of implementing updated reporting standards. As the evidence base expands, aligning screening protocols with real‑world cancer risk will be essential to maximize the public health payoff of nationwide lung‑cancer screening programs.